Front-line daratumumab-VTd versus standard-of-care in ASCT-eligible multiple myeloma: matching-adjusted indirect comparison
Aim: To compare daratumumab plus standard-of-care (SoC; bortezomib/thalidomide/dexamethasone [VTd]) and VTd alone with other SoC for transplant-eligible newly diagnosed multiple myeloma. Patients & methods: We conducted an unanchored matching-adjusted indirect comparison of progression-free and...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
February 2021
|
| In: |
Immunotherapy
Year: 2021, Jahrgang: 13, Heft: 2, Pages: 143-154 |
| ISSN: | 1750-7448 |
| DOI: | 10.2217/imt-2020-0266 |
| Online-Zugang: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.2217/imt-2020-0266 Verlag, lizenzpflichtig, Volltext: https://www.futuremedicine.com/doi/10.2217/imt-2020-0266 
|
| Verfasserangaben: | Philippe Moreau, Benjamin Hebraud, Thierry Facon, Xavier Leleu, Cyrille Hulin, Mahmoud Hashim, Yannan Hu, Denis Caillot, Lofti Benboubker, Sonja Zweegman, Maximilian Merz, Katja Weisel, Hans Salwender, Elias K Mai, Hartmut Goldschmidt, Uta Bertsch, Véronique Vanquickelberghe, Tobias Kampfenkel, Carla de Boer, Stanimira Krotneva, Irina Proskorovsky, Jianming He, Annette Lam, Charlene Lee, Sarah Cote, and Pieter Sonneveld |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1881498425 | ||
| 003 | DE-627 | ||
| 005 | 20240307091526.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240223s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.2217/imt-2020-0266 |2 doi | |
| 035 | |a (DE-627)1881498425 | ||
| 035 | |a (DE-599)KXP1881498425 | ||
| 035 | |a (OCoLC)1425217647 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Moreau, Philippe |e VerfasserIn |0 (DE-588)1095523767 |0 (DE-627)856146544 |0 (DE-576)463046390 |4 aut | |
| 245 | 1 | 0 | |a Front-line daratumumab-VTd versus standard-of-care in ASCT-eligible multiple myeloma |b matching-adjusted indirect comparison |c Philippe Moreau, Benjamin Hebraud, Thierry Facon, Xavier Leleu, Cyrille Hulin, Mahmoud Hashim, Yannan Hu, Denis Caillot, Lofti Benboubker, Sonja Zweegman, Maximilian Merz, Katja Weisel, Hans Salwender, Elias K Mai, Hartmut Goldschmidt, Uta Bertsch, Véronique Vanquickelberghe, Tobias Kampfenkel, Carla de Boer, Stanimira Krotneva, Irina Proskorovsky, Jianming He, Annette Lam, Charlene Lee, Sarah Cote, and Pieter Sonneveld |
| 264 | 1 | |c February 2021 | |
| 300 | |a 12 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Online veröffentlicht: 24 November 2020 | ||
| 500 | |a Gesehen am 23.02.2024 | ||
| 520 | |a Aim: To compare daratumumab plus standard-of-care (SoC; bortezomib/thalidomide/dexamethasone [VTd]) and VTd alone with other SoC for transplant-eligible newly diagnosed multiple myeloma. Patients & methods: We conducted an unanchored matching-adjusted indirect comparison of progression-free and overall survival (PFS/OS) with D-VTd/VTd versus bortezomib/lenalidomide/dexamethasone (VRd), bortezomib/cyclophosphamide/dexamethasone (VCd) and bortezomib/dexamethasone (Vd). Results: After matching adjustment, significant improvements in PFS were estimated for D-VTd versus VRd (hazard ratio [HR]: 0.47 [95% CI: 0.33-0.69]), VCd (HR: 0.35 [95% CI: 0.21-0.58]) and Vd (HR: 0.42 [95% CI: 0.28-0.63]). OS was significantly longer with D-VTd versus VRd (HR: 0.31 [95% CI: 0.16-0.57]), VCd (HR: 0.35 [95% CI: 0.14-0.86]) and Vd (HR: 0.38 [95% CI: 0.18-0.77]). No significant PFS/OS differences were seen for VTd versus other SoC. Conclusion: This analysis supports front-line daratumumab for transplant-eligible newly diagnosed multiple myeloma. | ||
| 650 | 4 | |a daratumumab | |
| 650 | 4 | |a multiple myeloma | |
| 650 | 4 | |a newly diagnosed | |
| 650 | 4 | |a standard of care | |
| 650 | 4 | |a transplant eligible | |
| 700 | 1 | |a Hebraud, Benjamin |e VerfasserIn |4 aut | |
| 700 | 1 | |a Facon, Thierry |e VerfasserIn |4 aut | |
| 700 | 1 | |a Leleu, Xavier |e VerfasserIn |4 aut | |
| 700 | 1 | |a Hulin, Cyrille |e VerfasserIn |4 aut | |
| 700 | 1 | |a Hashim, Mahmoud |e VerfasserIn |4 aut | |
| 700 | 1 | |a Hu, Yannan |e VerfasserIn |4 aut | |
| 700 | 1 | |a Caillot, Denis |e VerfasserIn |4 aut | |
| 700 | 1 | |a Benboubker, Lofti |e VerfasserIn |4 aut | |
| 700 | 1 | |a Zweegman, Sonja |e VerfasserIn |4 aut | |
| 700 | 1 | |a Merz, Maximilian |d 1985- |e VerfasserIn |0 (DE-588)1023626950 |0 (DE-627)718419278 |0 (DE-576)367168251 |4 aut | |
| 700 | 1 | |a Weisel, Katja |e VerfasserIn |4 aut | |
| 700 | 1 | |a Salwender, Hans |e VerfasserIn |4 aut | |
| 700 | 1 | |a Mai, Elias K. |d 1985- |e VerfasserIn |0 (DE-588)1049182545 |0 (DE-627)781300274 |0 (DE-576)403130999 |4 aut | |
| 700 | 1 | |a Goldschmidt, Hartmut |d 1956- |e VerfasserIn |0 (DE-588)102258023X |0 (DE-627)717003809 |0 (DE-576)365637386 |4 aut | |
| 700 | 1 | |a Bertsch, Uta |e VerfasserIn |0 (DE-588)1026849861 |0 (DE-627)727494163 |0 (DE-576)372176224 |4 aut | |
| 700 | 1 | |a Vanquickelberghe, Véronique |e VerfasserIn |4 aut | |
| 700 | 1 | |a Kampfenkel, Tobias |e VerfasserIn |4 aut | |
| 700 | 1 | |a Boer, Carla de |e VerfasserIn |4 aut | |
| 700 | 1 | |a Krotneva, Stanimira |e VerfasserIn |4 aut | |
| 700 | 1 | |a Proskorovsky, Irina |e VerfasserIn |4 aut | |
| 700 | 1 | |a He, Jianming |e VerfasserIn |4 aut | |
| 700 | 1 | |a Lam, Annette |e VerfasserIn |4 aut | |
| 700 | 1 | |a Lee, Charlene |e VerfasserIn |4 aut | |
| 700 | 1 | |a Cote, Sarah |e VerfasserIn |4 aut | |
| 700 | 1 | |a Sonneveld, Pieter |e VerfasserIn |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Immunotherapy |d London : Taylor & Francis, 2009 |g 13(2021), 2 vom: Feb., Seite 143-154 |h Online-Ressource |w (DE-627)600591891 |w (DE-600)2495964-9 |w (DE-576)398101108 |x 1750-7448 |7 nnas |a Front-line daratumumab-VTd versus standard-of-care in ASCT-eligible multiple myeloma matching-adjusted indirect comparison |
| 773 | 1 | 8 | |g volume:13 |g year:2021 |g number:2 |g month:02 |g pages:143-154 |g extent:12 |a Front-line daratumumab-VTd versus standard-of-care in ASCT-eligible multiple myeloma matching-adjusted indirect comparison |
| 856 | 4 | 0 | |u https://doi.org/10.2217/imt-2020-0266 |x Verlag |x Resolving-System |z lizenzpflichtig |3 Volltext |
| 856 | 4 | 0 | |u https://www.futuremedicine.com/doi/10.2217/imt-2020-0266 |x Verlag |z lizenzpflichtig |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20240223 | ||
| 993 | |a Article | ||
| 994 | |a 2021 | ||
| 998 | |g 1026849861 |a Bertsch, Uta |m 1026849861:Bertsch, Uta |d 910000 |d 910100 |e 910000PB1026849861 |e 910100PB1026849861 |k 0/910000/ |k 1/910000/910100/ |p 16 | ||
| 998 | |g 102258023X |a Goldschmidt, Hartmut |m 102258023X:Goldschmidt, Hartmut |d 910000 |d 910100 |e 910000PG102258023X |e 910100PG102258023X |k 0/910000/ |k 1/910000/910100/ |p 15 | ||
| 998 | |g 1049182545 |a Mai, Elias K. |m 1049182545:Mai, Elias K. |d 910000 |d 910100 |e 910000PM1049182545 |e 910100PM1049182545 |k 0/910000/ |k 1/910000/910100/ |p 14 | ||
| 998 | |g 1023626950 |a Merz, Maximilian |m 1023626950:Merz, Maximilian |d 910000 |d 910100 |e 910000PM1023626950 |e 910100PM1023626950 |k 0/910000/ |k 1/910000/910100/ |p 11 | ||
| 999 | |a KXP-PPN1881498425 |e 4490405448 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"id":{"doi":["10.2217/imt-2020-0266"],"eki":["1881498425"]},"relHost":[{"title":[{"title_sort":"Immunotherapy","title":"Immunotherapy"}],"note":["Gesehen am 28.05.2024"],"pubHistory":["1.2009 -"],"origin":[{"publisherPlace":"London ; London","dateIssuedKey":"2009","publisher":"Taylor & Francis ; Future Medicine Ltd","dateIssuedDisp":"2009-"}],"disp":"Front-line daratumumab-VTd versus standard-of-care in ASCT-eligible multiple myeloma matching-adjusted indirect comparisonImmunotherapy","type":{"media":"Online-Ressource","bibl":"periodical"},"recId":"600591891","physDesc":[{"extent":"Online-Ressource"}],"id":{"eki":["600591891"],"issn":["1750-7448"],"zdb":["2495964-9"]},"language":["eng"],"part":{"volume":"13","extent":"12","year":"2021","pages":"143-154","issue":"2","text":"13(2021), 2 vom: Feb., Seite 143-154"}}],"recId":"1881498425","physDesc":[{"extent":"12 S."}],"name":{"displayForm":["Philippe Moreau, Benjamin Hebraud, Thierry Facon, Xavier Leleu, Cyrille Hulin, Mahmoud Hashim, Yannan Hu, Denis Caillot, Lofti Benboubker, Sonja Zweegman, Maximilian Merz, Katja Weisel, Hans Salwender, Elias K Mai, Hartmut Goldschmidt, Uta Bertsch, Véronique Vanquickelberghe, Tobias Kampfenkel, Carla de Boer, Stanimira Krotneva, Irina Proskorovsky, Jianming He, Annette Lam, Charlene Lee, Sarah Cote, and Pieter Sonneveld"]},"type":{"media":"Online-Ressource","bibl":"article-journal"},"title":[{"subtitle":"matching-adjusted indirect comparison","title_sort":"Front-line daratumumab-VTd versus standard-of-care in ASCT-eligible multiple myeloma","title":"Front-line daratumumab-VTd versus standard-of-care in ASCT-eligible multiple myeloma"}],"note":["Online veröffentlicht: 24 November 2020","Gesehen am 23.02.2024"],"origin":[{"dateIssuedKey":"2021","dateIssuedDisp":"February 2021"}],"language":["eng"],"person":[{"given":"Philippe","role":"aut","family":"Moreau","display":"Moreau, Philippe"},{"display":"Hebraud, Benjamin","family":"Hebraud","role":"aut","given":"Benjamin"},{"role":"aut","given":"Thierry","family":"Facon","display":"Facon, Thierry"},{"family":"Leleu","display":"Leleu, Xavier","role":"aut","given":"Xavier"},{"given":"Cyrille","role":"aut","display":"Hulin, Cyrille","family":"Hulin"},{"given":"Mahmoud","role":"aut","display":"Hashim, Mahmoud","family":"Hashim"},{"given":"Yannan","role":"aut","family":"Hu","display":"Hu, Yannan"},{"family":"Caillot","display":"Caillot, Denis","given":"Denis","role":"aut"},{"given":"Lofti","role":"aut","family":"Benboubker","display":"Benboubker, Lofti"},{"family":"Zweegman","display":"Zweegman, Sonja","role":"aut","given":"Sonja"},{"role":"aut","given":"Maximilian","display":"Merz, Maximilian","family":"Merz"},{"display":"Weisel, Katja","family":"Weisel","role":"aut","given":"Katja"},{"family":"Salwender","display":"Salwender, Hans","role":"aut","given":"Hans"},{"given":"Elias K.","role":"aut","family":"Mai","display":"Mai, Elias K."},{"family":"Goldschmidt","display":"Goldschmidt, Hartmut","given":"Hartmut","role":"aut"},{"family":"Bertsch","display":"Bertsch, Uta","role":"aut","given":"Uta"},{"given":"Véronique","role":"aut","family":"Vanquickelberghe","display":"Vanquickelberghe, Véronique"},{"given":"Tobias","role":"aut","family":"Kampfenkel","display":"Kampfenkel, Tobias"},{"given":"Carla de","role":"aut","family":"Boer","display":"Boer, Carla de"},{"role":"aut","given":"Stanimira","display":"Krotneva, Stanimira","family":"Krotneva"},{"display":"Proskorovsky, Irina","family":"Proskorovsky","role":"aut","given":"Irina"},{"given":"Jianming","role":"aut","display":"He, Jianming","family":"He"},{"given":"Annette","role":"aut","family":"Lam","display":"Lam, Annette"},{"role":"aut","given":"Charlene","display":"Lee, Charlene","family":"Lee"},{"family":"Cote","display":"Cote, Sarah","role":"aut","given":"Sarah"},{"display":"Sonneveld, Pieter","family":"Sonneveld","role":"aut","given":"Pieter"}]} | ||
| SRT | |a MOREAUPHILFRONTLINED2021 | ||